In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline

Journal of Antibiotics

Volumn 69, Issue 8, 2016, Pages 600-604

  Zhang, Yunliang ^a   Lin, Xiaoyan ^a   Bush, Karen ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEMASE; CEFOTAXIME; CEFTAZIDIME; ERAVACYCLINE; IMIPENEM; LEVOFLOXACIN; METALLO BETA LACTAMASE; TETRACYCLINE; TIGECYCLINE; 7-FLUORO-9-PYRROLIDINOACETAMIDO-6-DEMETHYL-6-DEOXYTETRACYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG POTENCY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SERRATIA MARCESCENS; COMPARATIVE STUDY; DRUG EFFECTS; ENTEROBACTERIACEAE; ENZYMOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; TETRACYCLINES;

EID: 84984815298     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2016.73     Document Type: Article

References (35)

1. Centers for Disease Control, and Prevention. Antibiotic Resistance Threats in the United States (United States Department of Health, and Human Services, Atlanta, GA, USA, 2013
2. Drekonja, D. M., et al. Challenges in the management of infections due to carbapenemresistant Enterobacteriaceae. Infect. Control Hosp. Epidemiol. 35, 437-439 (2014
3. Satlin, M. J., Jenkins, S. G., & Walsh, T. J. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients, and patients with hematologic malignancies. Clin. Infect. Dis. 58, 1274-1283 (2014
4. Bassetti, M., & Righi, E. New antibiotics, and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr. Opin. Crit. Care 21, 402-411 (2015
5. Bush, K. Investigational agents for the treatment of Gram-negative bacterial infections: a reality check. ACS Infect. Dis. 1, 509-511 (2015
6. Amin, A. N., & Deruelle, D. Healthcare-associated infections, infection control, and the potential of new antibiotics in development in the USA. Future Microbiol. 10, 1049-1062 (2015
7. Page, M. G. P., & Bush, K. Discovery, and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr. Opin. Pharmacol. 18, 91-97 (2014
8. Bush, K. A resurgence of β-lactamase inhibitor combinations effective against multidrugresistant Gram-negative pathogens. Intl. J. Antimicrob. Agents 46, 483-493 (2015
9. Infectious Diseases Society of Americaet al. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52(suppl. 5), S397-S428 (2011
10. Abdallah, M., et al. Activity of eravacycline against Enterobacteriaceae, and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob. Agents Chemother. 59, 1802-1805 (2015
11. Sutcliffe, J. A., O'Brien, W., Fyfe, C., & Grossman, T. H. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital, and community pathogens. Antimicrob. Agents Chemother. 57, 5548-5558 (2013
12. Grossman, T. H., et al. Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob. Agents Chemother. 56, 2559-2564 (2012
13. Grossman, T. H., O'Brien, W., Kerstein, K. O., & Sutcliffe, J. A. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob. Agents Chemother. 59, 2446-2449 (2015
14. Grossman, T. H., Murphy, T. M., Slee, A. M., Lofland, D., & Sutcliffe, J. A. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob. Agents Chemother. 59, 2567-2571 (2015
15. Solomkin, J. S., et al. Phase 2, randomized, double-blind study of the efficacy, and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob. Agents Chemother. 58, 1847-1854 (2014
16. Livermore, D. M., Mushtaq, S., Warner, M., & Woodford, N. Activity of eravacycline against carbapenemase-producing Enterobacteriaceae, and Acinetobacter baumannii. Abstract F-769. in 55th Interscience Conference on Antimicrobial Agents, and Chemotherapy (San Diego, CA, USA, 2015
17. Zhanel, G. G., et al. Activity of eravacycline, and comparators against 3, 174 pathogens isolated from Canadian hospitals: CANWARD 2014. Abstract F-771. in 55th Interscience Conference on Antimicrobial Agents, and Chemotherapy (San Diego, CA, USA, 2015
18. Denys, G. A., et al. Changing epidemiology, and molecular characterization of carbapenem-resistant Enterobacteriaceae (CRE) in Indiana Health Care Centers (HCCs) over a 3-year period. Abstract # C2-1445. in: 53rd Conf. Antimicrobial Agents, and Chemotherapy (Denver, CO, USA, 2013
19. Bush, K., et al. Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. Intl. J. Antimicrob. Agents 41, 1-4 (2013
20. Dunn, M., et al. KPC-2, and VIM carbapenemases decreased in carbapenem-resistant Enterobacteriaceae in Indiana health care centers from 2009 to 2013. in 54th Interscience Conference on Antimicrobial Agents, & Chemotherapy (Washington, DC, USA, 2014
21. Kashikar, A., et al. Occurrence of VIM, and NDM carbapenemases in Indiana health care centers from 2009 to 2013. Abstract C-1095. in 55th Interscience Conference on Antimicrobial Agents, and Chemotherapy (San Diego, CA, USA, 2015
22. CLSI Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100S, 26th edn (Clinical, and Laboratory Standards Institute, Wayne, PA, 2016
23. Nordmann, P., Poirel, L., & Dortet, L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 18, 1503-1507 (2012
24. Fairfax, M. R., et al. Detection of 2 SME-1 carbapenemase-producing Serratia marcescens in Detroit. Diagn. Microbiol. Infect. Dis. 71, 325-326 (2011
25. Queenan, A. M., et al. SME-type carbapenem-hydrolyzing class A β-lactamases from geographically diverse Serratia marcescens strains. Antimicrob. Agents Chemother. 44, 3035-3039 (2000
26. Yigit, H., et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenemresistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45, 1151-1161 (2001
27. Lolans, K., Queenan, A. M., Bush, K., Sahud, A., & Quinn, J. P. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-β-lactamase (VIM-2) in the United States. Antimicrob. Agents Chemother. 49, 3538-3540 (2005
28. Queenan, A. M., et al. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother. 50, 3485-3487 (2006
29. Sidjabat, H., et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother. 53, 4733-4739 (2009
30. Poirel, L., Walsh, T. R., Cuvillier, V., & Nordmann, P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn. Microbiol. Infect. Dis. 70, 119-123 (2011
31. CLSI. M07-A9: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 9th edn (Clinical, and Laboratory Standards Institute, Wayne, PA, 2013
32. Johnson, J. R., Porter, S. B., Johnston, B. D., & Thuras, P. Activity of eravacycline against Escherichia coli clinical isolates collected from U.S. veterans in 2011 in relation to coresistance phenotype, and sequence type 131 genotype. Antimicrob. Agents Chemother 60, 1888-1891 (2015
33. Castanheira, M., Farrell, S. E., Krause, K. M., Jones, R. N., & Sader, H. S. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions, and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother. 58, 833-838 (2014
34. Centers for Disease Control, & Prevention. Notes from the field: New Delhi metallo-β-lactamase-producing Escherichia coli associated with endoscopic retrograde cholangiopancreatography -Illinois, 2013. Morbid. Mortal. Week Rep. 62, 1051 (2014
35. Li, H., et al. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 59, 1789-1793 (2015